EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study
Go back to EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study| (NASDAQ: EYEG) | Delayed: 34.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.95 | 52 Week High | $5.09 | |||
| Open | $34.95 | 52 Week Low | $1.11 | |||
| Day High | $34.95 | P/E | N/A | |||
| Day Low | $34.95 | EPS | $0.00 | |||
| Volume | 14 | |||||

